Satsuma Pharmaceuticals, Inc.
Rigrodsky Law, P.A. is investigating Satsuma Pharmaceuticals, Inc. (“Satsuma”) regarding possible breaches of fiduciary duties and other violations of law related to Satsuma’s agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the agreement, Satsuma shareholders will receive $0.91 per share in cash.